BOSTON, April 27, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data from a Phase 2 study of elobixibat in chronic constipation conducted by EA Pharma Co., Ltd. in Japan is scheduled to be presented at Digestive Disease Week (DDW) 2017.
Elobixibat is a once-daily, orally available ileal bile acid transporter (IBAT) inhibitor that is believed to improve both secretion and motility in the large bowel. EA Pharma, a subsidiary of Eisai Co., Ltd. focused in the gastrointestinal disease space, is the exclusive licensee of elobixibat for the treatment of gastrointestinal disorders in Japan and other select countries in Asia.
Subsequent to completion of the Phase 2 clinical trial being presented at DDW, EA Pharma conducted a Phase 3 trial of elobixibat in chronic constipation with positive results and submitted an application for regulatory approval in Japan. Subject to receipt of regulatory approval, EA Pharma plans to co-market elobixibat in Japan with Mochida Pharmaceutical Co., Ltd.
Details of the DDW presentation are as follows:
Title:§ Determining a clinical optimal dose of elobixibat, a novel IBAT inhibitor, in Japanese patients with chronic constipation: a multicenter, randomized, double-blind, placebo-controlled study
Abstract Number: 172
Session:§ Constipation and Colorectal Disorders
Session Number: 2445
Date / Time: Saturday, May 6, 4:00-4:12 p.m. CDT
Location:§ S406b, McCormick Place in Chicago
Presenter:§ Atsushi Nakajima, MD, PhD; Division of Hepatogastroenterology, Yokohama City University Graduate School of Medicine, Japan
|